antifungal agent 1

Antifungal agent 1 is an effective antifungal agent.

Antifungal agent 76 has broad-spectrum antifungal activity with a MIC value of 0.25-16 μg mL.Antifungal agent 76 may act by disrupting fungal cell membranes and can be used to study fungal infections.

Antiulcer Agent 1 is an orally administered derivative of 2-(3,4-dimethoxyphenyl)ethylamine.

Anxiolytic/nonsedative agent-1 (TCS 1205) is a potent and selective GABAA agonist. Anxiolytic/nonsedative agent-1 shows appreciable affinity for the BzR in bovine brain membranes with Kis of 14, 121, 239 nM for α1β2γ2, α2β2γ2, α5β3γ2, respectively. Anxiolytic/nonsedative agent-1 shows α2 selective efficacy in vitro and anxioselective effects in vivo.

Anti-TB agent 1 is a potent and orally active anti-tuberculosis compound (MICs: < 2 nM against the Mtb strains H37Rv, rRMP, and rINH).

ethyl 2-[3,5-bis(trifluoromethyl)phenyl]-3-oxo-2,3-dihydro-1H-pyrazole-4-carboxylate is a synthetic compound belonging to the curcumin family. It is involved in the regulation of immune response and inflammation through inhibition of the NF-κB signaling pathway, in the regulation of antioxidant response through activation of the Nrf2 signaling pathway, and in the regulation of cell survival and proliferation through inhibition of the Akt signaling pathway.

Acetic acid, 2-[4-[(2-ethyl-3-benzofuranyl)carbonyl]phenoxy]- is a compound used for antiviral activity determinations.

Antifungal agent 6 shows antifungal activity.

Anticonvulsant agent 1 is a chemical compound with potent anticonvulsant properties.

GABAA receptor agent 1 has strong anticonvulsant activity and is a high affinity ligand of GABAA receptor.

Antitrypanosomal agent 1 is a potent and selective trypanothione reductase (TR) inhibitor (IC50: 3.3 μM) that also inhibits glutathione reductase (IC50: 64.8 μM) and T. brucei (EC50: 1 μM).

Antimalarial agent 1 is an effective antimalarial agent.

Antifungal agent 100 (compound 3i) demonstrates notable antifungal activity, exhibiting an EC 50 of 0.33 mg L against S. sclerotiorum. It also possesses an IC 50 value of 0.63 mg mL targeting the Succinate dehydrogenase (SDH) of the same organism [1].

Antifungal Agent 61 (Compound 38) is an antifungal agent that inhibits V. mali, with an EC50 value of 0.50 mg/L. This compound impedes V. mali's growth by inducing cell deformation and contraction, diminishing intracellular mitochondrial count, thickening the cell wall, and enhancing cell membrane permeability [1].

Compound 9 (Antifungal agent 67), an imidazole class antifungal, exhibits efficacy against Candida and possesses a CC50 value of 33.6 μM in neonatal rat cardiomyoblasts [1].

Antifungal agent 68 (compound 10) effectively combats fungal infections caused by Candida and Cryptococcus gattii through the inhibition of ergosterol biosynthesis, likely via interaction with lanosterol 14α-demethylase (CYP51). The imidazole ring of antifungal agent 68 is proposed to interact with the heme group of CYP51 [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane, demonstrating potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].

Antifungal agent 50 exhibits minimum inhibitory concentrations (MICs) ranging from less than 0.063 to 1 μg/mL [1].

Antifungal agent 54 (compound A05) is a potent inhibitor against Fluconazole-resistant strains, outperforming Miconazole in efficacy. It exhibits significant activity against Candida albicans, with minimum inhibitory concentration (MIC) values ranging from 0.25-1 μg mL [1].

Antifungal Agent 29 (compound 9d) is a potent, selective, and non-toxic agent effective against Cryptococcus neoformans, exhibiting an MIC of ≤0.23 μM [1].

Pradimicin A derivative 26 exhibits antifungal, antiviral, and antiparasitic properties by attaching to d-mannose (Man)-rich glycans in pathogenic organisms [1].

Antifungal agent 51 (5c) exhibits potent antifungal activity against Candida albicans FDC 151, Candida parapsilosis ATCC 22019, and Candida tropicalis FDC 138, with a minimum inhibitory concentration (MIC) value of less than 0.063 μg/mL. It demonstrates low toxicity to cells and no carcinogenicity [1].

Compound 24f, an antifungal agent also known as 'Antifungal agent 85,' demonstrates potent antibacterial properties, exhibiting minimum inhibitory concentration (MIC) values ranging from 2.5 to 10 μM against diverse Gram-positive bacteria [1].

Antioxidant anticancer agent 1 (compound 5) is a Schiff base derivative of pyrimidine and pyrimidine hydroxy-1-naphthaldehyde, exhibiting antibacterial, antioxidant, antifungal, and anticancer properties [1].

Antifungal agent 72 (Compound B8) demonstrates potent activity by inhibiting the efflux pump function and downregulating resistance-associated genes via disruption of the Pdr1-KIX interaction (K i : 11.7 μM). It exhibits efficacy against Fluconazole-resistant strains, evidenced by a MIC of 63 ng mL, and displays synergistic effects when combined with Fluconazole. This compound is particularly useful for researching C. glabrata infections [1].

Antifungal agent 78 (compound 25am) shows potent activity against Fusarium graminearum with an EC50 of 13.46 μM [1].

Antifungal agent 47 (compound 3b) exhibits potent and broad-spectrum fungicidal properties, notably inhibiting respiration and adenosine 5′-triphosphate synthesis, demonstrating its potential as an effective fungicide [1].

Antifungal agent 58 (compound A21) demonstrates high potency against Fluconazole-resistant strains and surpasses Miconazole in effectiveness, inhibiting Candida albicans with minimum inhibitory concentration (MIC) values ranging from 0.06 to 8 μg mL [1].

Antibacterial Agent 84, an antifungal compound, effectively inhibits candidiasis through a CNB1-dependent mechanism and reduces the viability of the C. albicans biofilm [1].

Antifungal agent 48 (Example 308), active against Cryptococcus neoformans, exhibits a minimum inhibitory concentration (MIC) value of 11 μM [1].

Antifungal agent 82 (compound G34) exhibits outstanding in vitro antifungal efficacy against Valsa mali, with an EC50 value of 0.57 μg mL, and demonstrates excellent in vivo protective effects at 40 μg mL [1].

Compound 3a (Antifungal agent 62) exhibits potent fungicidal properties, particularly against Fusarium oxysporum f.sp. cucumerinum, and is utilized in antiviral and fungicidal research [1].

Compound CN21b (Antifungal agent 95) serves as an effective antifungal agent targeting Sclerotinia sclerotiorum and Botrytis cinerea, achieving EC50s of 2.11 μM and 0.97 μM, respectively. This compound also demonstrates potent activity against resistant B. cinerea strains, maintaining EC50 values below 10 μM [1].

Antifungal agent 92 (Compound 21) exhibits significant efficacy with an EC50 value of 4.4 μM against Sclerotinia sclerotiorum. It disrupts mitochondrial functions by inducing abnormal morphology, reducing membrane potential, and promoting the accumulation of reactive oxygen species (ROS) in the pathogen. Additionally, it moderately inhibits mitochondrial complexes II and III, showcasing its promiscuous inhibitory activity [1].

Antifungal agent 69 (compound 13), a eugenol-imidazole derivative, demonstrates targeted activity against Candida albicans with a minimum inhibitory concentration (MIC) of 4.6 μM, while exhibiting negligible cytotoxicity. This compound disrupts ergosterol biosynthesis, contributing to its antifungal efficacy [1].

Antifungal agent 66 (compound 10) demonstrates broad-spectrum antifungal activity against seven phytopathogenic fungal mycelia and provides significant inhibitory effects on the spores of B. cinerea, with an IC50 value of 47.7 μg mL [1].

Antifungal agent 27 (compound 7) is a chemical compound with antifungal properties, exhibiting moderate antibacterial activity and weak antifungal activity against MRSA and C. albicans SS5314, with minimal inhibitory concentration (MIC) values of 8 and 32 μg mL, respectively [1].

Antifungal Agent 53 (A03), a potent Candida albicans CYP51 inhibitor, exhibits antifungal activity by preventing fungi biofilm formation and demonstrates good safety [1].

Antifungal agent 55 (Compound A07) effectively inhibits Fluconazole-resistant strains of Candida albicans, demonstrating greater efficacy than Miconazole. It exhibits minimum inhibitory concentrations (MIC) values ranging from 0.25-1 μg/mL [1].

Antifungal agent 56 (compound A09) is a potent antifungal, demonstrating superior efficacy against Fluconazole-resistant strains and outperforming Miconazole, effectively inhibiting Candida albicans strains with minimal inhibitory concentration (MIC) values ranging from 0.03 to 0.25 μg mL [1].

Antifungal agent 32 (compound 1a) is a highly effective antifungal compound that strongly inhibits Candida albicans filamentation, biofilm formation, morphological switching, and adherence to epithelial cells, making it a valuable tool for research on Candida albicans infections [1].

Antifungal agent 81(G22) exhibits excellent antifungal properties, demonstrating an in vitro IC50 value of 0.48 mg/L against Valsa mali. Moreover, it also shows robust in vivo protection against V. mali at a concentration of 40 mg/L [1].

Antifungal agent 90 (Compound 7n), known for inhibiting ergosterol biosynthesis, demonstrates potent antifungal activity. It exhibits effective control against Valsa mali and Botrytis cinerea, with EC 50 values of 4.26 and 1.41 μg mL, respectively [1].

Antifungal agent 38 is a heterocyclic disulfide with antifungal and antibacterial properties. It induces hyphal shrinkage, disrupts plasma membrane integrity, and causes cell content damage and leakage [1].

Antifungal agent 74 (compound 3c), is a potent substance that exhibits excellent fungicidal activity against C. arachidicola and R. solani, functioning by disrupting steroid biosynthesis and ribosome biogenesis in eukaryotes [1].

Antifungal Agent 70 (Compound 13), a dihydroeugenol-imidazole, exhibits efficacy against multi-resistant Candida auris with a minimum inhibitory concentration (MIC) of 36.4 μM, demonstrating notable antifungal activity [1].

Compound 5c (Antifungal agent 64) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is applicable for research in antiviral and fungicidal domains [1].

Compound 5d (Antifungal Agent 65) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is utilized in antiviral and fungicidal research [1].

Voriconazole (UK-109496) camphorsulfonate, a second-generation broad-spectrum triazole antifungal compound, inhibits fungal ergosterol biosynthesis by targeting the P450-mediated demethylation of 14-alpha-lanosterol.

Voriconazole (UK-109496) is a triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 [CYP3A].

Voriconazole-d3 is a deuterated compound of Voriconazole. Voriconazole has a CAS number of 137234-62-9. Voriconazole is a triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.